![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Publisher: Adis International
ISSN: 1173-8324
Source: Inpharma, Vol.1, Iss.1490, 2005-01, pp. : 13-14
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Docetaxel regimen improves survival in early breast cancer
Inpharma, Vol. 1, Iss. 1475, 2005-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
TAC regimen improves survival in early breast cancer
Inpharma, Vol. 1, Iss. 1424, 2004-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
In defence of trastuzumab for early breast cancer
Inpharma, Vol. 1, Iss. 1521, 2006-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Trastuzumab prolongs survival in metastatic breast cancer
Inpharma, Vol. 1, Iss. 1498, 2005-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Trastuzumab without an anthracycline: better for early breast cancer
Inpharma, Vol. 1, Iss. 1574, 2007-01 ,pp. :